The Check Is Real. The “Income” Is a Mind Trick.

A dividend feels like a paycheck: it arrives on schedule and never asks you to sell anything. Wednesday's Journal column showed what that feeling costs. Today we turn its lesson into house policy — including a formal review of a stock we own.

By Sean Anees Saifi · Capital Wealth · Published Thursday, August 6, 2026 · Source: The Wall Street Journal, August 6, 2026 (Spencer Jakab, “Heard on the Street”)

Key Points

Over ten years, high-dividend stocks returned 3.9% a year; the plain S&P 500 returned 13.2%.
When a company pays a dividend, its stock price drops by that amount — and you get taxed.
Pfizer's 6.9% dividend now eats nearly all the cash its business generates.
New house rule: a dividend must be covered about twice over by earnings.
We own Pfizer in our income holdings, so it goes under formal review this weekend.

3.9%

Yearly return of high-dividend stocks, past decade

13.2%

Yearly return of the plain S&P 500

6.9%

Pfizer's dividend yield — the warning sign

~2x

Earnings coverage we now require

The question is never what a stock yields. The question is who is paying for it — the business, or the shareholder's own future.

In one line: A big dividend can quietly cost you growth, so we now require every dividend stock we hold to earn about twice what it pays out. Pfizer, which we own, is under review.

A dividend feels like a paycheck. It arrives on schedule, it never asks how the stock is doing, and it lets you feel income without selling anything. On Wednesday, the Journal's Spencer Jakab called that feeling what it is: a mind trick.

His headline number is brutal. Over the past decade, the S&P 500 High Dividend Index — a basket of the market's biggest dividend payers — returned 3.9% a year. The plain S&P 500 returned 13.2%. The people who reached hardest for income gave up most of the growth.

Here is the mechanism, because it never stops being surprising. When a company pays a dividend, its stock price drops by roughly the same amount. The money moved from one of your pockets to the other — and got taxed on the way.

And now that stock trades are free, the old excuse is gone. Selling a few shares gives you the same income, on your own schedule, often at better tax rates. Calling the dividend “income” and the stock price “savings” is a comforting mental trick. Still a trick.

The warning list

The column's main exhibit is Pfizer (PFE), which yields 6.9% — meaning the yearly dividend equals 6.9% of the stock price. From 2020 through mid-2023, Pfizer spent 42% of its free cash flow — the cash left over after running the business — on dividends. Today the dividend eats nearly all of that cash.

Alongside it: Kraft Heinz (KHC), General Mills (GIS), Verizon (VZ), Altria (MO), Campbell's (CPB) and UPS (UPS). As a group, their earnings are growing at less than 1% a year, and they trade at 9.8 times their yearly earnings, while the average stock in the index trades at 25 times. That is not the market missing a bargain. That is the market pricing companies that mail out their seed corn.

Our new house rule

We run income portfolios — the Midterm Dividend series exists because our clients want income. So we are not reading this column as an attack. We are reading it as a quality-control manual, and we are adopting its core idea today.

Call it the coverage test. A dividend covered about twice over by earnings is a share of real profits — the business pays you. A dividend that consumes all the company's spare cash is a slow-motion refund of your own money, dressed up as income.

Tuesday's energy purchases already pass the test. Chevron (CVX) raised its dividend with record earnings covering the payout roughly two times over. Williams (WMB) pays its distribution from pipeline fees that arrive whether oil is $70 or $110. Payers with coverage — not payouts with hope. (The full case is in Tuesday's companion piece: the oil windfall and where it went.)

The uncomfortable part

A policy you only apply to new purchases is a slogan. So here is the honest bit: Pfizer sits in our own $500K Midterm Dividend portfolio. A 6.9% yield eating nearly all the company's spare cash is exactly the pattern the column warns about.

So Pfizer goes under formal review as of today: how well the dividend is covered, where the payout is heading, and what the business would look like if the dividend were sized honestly. The decision comes at the weekend recap.

Not a panic sale. A review. Every holding has to re-earn its seat — especially the ones that pay us to stop asking questions.

What It Means For Your Portfolio

One holding under review

The coverage test is now house policy, and our own Pfizer position is the first stock to face it.

Our income holdings keep dividend payers whose earnings cover the payout about twice over — Chevron and Williams both pass. Pfizer, held in our $500K Midterm Dividend portfolio, may not, so it goes under formal review with a decision at the weekend recap. Your income plan is built on total return — the dividend plus the change in the stock price, added together; a dividend is a tool inside it, not a paycheck, and never a reason to hold a shrinking business.